Psychedelic Alpha

On Tuesday, we covered Compass Pathways’ readout covering 26-week data from its second Phase 3 study of COMP360 psilocybin for treatment-resistant depression (TRD): Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch. After our initial reporting published, the company shared more detailed slides (PDF) as well as prepared remarks on a webcast, which was fol...

This morning, Compass Pathways shared 26-week data from its second Phase 3 study of COMP360 psilocybin for treatment-resistant depression (TRD). The data are from Part B of COMP006, the company’s larger (n=581) Phase 3 trial that initially assessed two doses of either 1 mg, 10 mg, or 25 mg of psilocybin 3 weeks apart. The primary endpoint was met, Compass shared in February, ...

Welcome to our Q2 2026 Quarterly Briefing. Every three months, our Founder & Editor Josh Hardman walks you through major developments from the prior quarter across drug development, policy and regulation, science and academia, and much more. He closes with a look ahead to the next quarter, so you know what to look out for.

A Case Report published in Frontiers in Neuroscience late last month (Lago et al., 2026) caused quite a stir, with various media outlets and psychedelics advocates hailing it as showing great promise. It reported on a woman in her 80s who has had Alzheimer’s for a decade being repeatedly dosed with psilocybin and apparently experiencing functional improvements thereafter. We ...